Free Trial
CVE:RX

BioSyent 8/26/2024 Earnings Report

BioSyent logo
C$10.50 +0.25 (+2.44%)
As of 04/25/2025 02:29 PM Eastern

BioSyent EPS Results

Actual EPS
C$0.13
Consensus EPS
C$0.13
Beat/Miss
Met Expectations
One Year Ago EPS
N/A

BioSyent Revenue Results

Actual Revenue
$8.95 million
Expected Revenue
$8.80 million
Beat/Miss
Beat by +$150.00 thousand
YoY Revenue Growth
N/A

BioSyent Announcement Details

Quarter
Time
N/A
Conference Call Date
N/A
Conference Call Time
N/A

Conference Call Resources

BioSyent Earnings Headlines

Trump’s Secret Social Security Plan?
In less than a decade, Social Security could be out of money. But a surprising plan from Trump’s inner circle may not just save the system — it could unlock a major opportunity for savvy investors. Financial insider Jim Rickards calls it “Social Prosperity,” and says those who act now could see the biggest gains.
BioSyent Inc. (RX.V)
See More BioSyent Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like BioSyent? Sign up for Earnings360's daily newsletter to receive timely earnings updates on BioSyent and other key companies, straight to your email.

About BioSyent

BioSyent (CVE:RX), together with its subsidiaries, acquires or licenses, develops, and sells pharmaceutical and other healthcare products in Canada and internationally. Its products include FeraMAX Pd Therapeutic 150 for the treatment of iron deficiency anemia; FeraMAX Pd Maintenance 45, a chewable supplement for the prevention of iron deficiency anemia; and FeraMAX Pd Powder 15, a powder form product used for preventing iron deficiency and iron deficiency anemia. It offers Tibella, a hormone replacement therapy consisting of tibolone; Inofolic, a natural health product to address polycystic ovarian syndrome symptoms; RepaGyn, a vaginal suppository for the healing of the vaginal mucosa, as well as for the treatment of vaginal dryness caused by aging, menopause, stress, and chemotherapy; and Gelclair, a gel formulated to aid the pain or oral mucositis. In addition, the company provides Cathejell, a lubricant with anesthetic with the indication of lubricating and opening the urethra before the insertion of the catheter; Combogesic to manage mild to moderate acute pain and reduction of fever in adults; and Proktis-M, a rectal suppository for the healing of the anus and rectum. The company sells its products through wholesalers and retail pharmacy chains. The company was formerly known as Hedley Technologies Inc. and changed its name to BioSyent Inc. in June 2006. BioSyent Inc. was founded in 2006 and is headquartered in Mississauga, Canada.

View BioSyent Profile

More Earnings Resources from MarketBeat